TheStreet’s Jim Cramer says investors should own Allergan because the stock is undervalued. Cramer says Allergan will benefit from the closing of the sale of its generics business to Teva Pharmaceuticals for $40.5 billion.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
